Big pharma eyes Australian biotech as $300b patent cliff looms

Why Novartis’s $2b deal is a turning point for Australian biotech

A $2 billion biotech deal has one investor salivating at the prospect of more lucrative M&A deals in the sector as global pharma firms set sights on Australia.